Диссертация (1174247), страница 18
Текст из файла (страница 18)
201593. Lau Y. Hypertension and atrial fibrillation: epidemiology, pathophysiology andtherapeutic implications /Lau Y., Yiu K., Siu C., et al. // J Hum Hypertens. 2012Oct; 26(10):563–9.94. Lee D. Relation of disease pathogenesis and risk factors to heart failure withpreserved or reduced ejection fraction: Insights from the Framingham Heart118Study of the National Heart, Lung, and Blood Institute / Lee D., Gona P., VasanR., et al. // Circulation. 2009; 119:3070–3077.95. Le Heuzey J. The RecordAF study: design, baseline data, and profile of patientsaccording to chosen treatment strategy for atrial fibrillation / Le Heuzey J.,Breithardt G., Camm J., et al.
// Am J Cardiol 2010; 105: 687–693.96. LeWinter M. Mechanisms of diastolic dysfunction in heart failure with apreserved ejection fraction: If it’s not one thing it’s another / LeWinter M., MeyerM. // Circ Heart Fail 2013; 6: 1112–1115.97. Li J. Current treatment of heart failure with preserved ejection fraction: shouldwe add life to the remaining years or add years to the remaining life? / Li J.,Becher P., Blankenberg S., et al. // Cardiol Res Pract. 2013; 2013:130724.98.Lim H. Effects of iatrogenic myocardial injury on coronary microvascularfunction in patients undergoing radiofrequency catheter ablation of atrialfibrillation / Lim H., Choi C., Na J., et al.
// Circ Arrhythm Electrophysiol. 2013Apr;6(2):318–26.99.Liu G. Meta-analysis of the effect of statins on mortality in patients withpreserved ejection fraction / Liu G. Zheng X., Xu Y., et al. // Am J Cardiol. 2014Apr 1; 113(7):1198–204.100.Lorgat F. Robotically controlled ablation for atrial fibrillation: the first real-world experience in Africa with the Hansen robotic system / Lorgat F., PudneyE., van Deventer H., et al.
// Cardiovasc J Afr. 2012 Jun; 23(5):274–80.101.Machino-Ohtsuka T. Significant improvement of left atrial and left atrialappendage function after catheter ablation for persistent atrial fibrillation /Machino-Ohtsuka T., Seo Y., Ishizu T., et al. // Circ J. 2013; 77(7):1695–704.102.Maier L. RAnoLazIne for the treatment of diastolic heart failure in patientswith preserved ejection fraction: the RALI-DHF proof-of-concept study / MaierL., Layug B., Karwatowska-Prokopczuk E., et al. // JACC Heart Fail. 2013;1:115–122.119103.Mainigi S.
Incidence and predictors of very late recurrence of atrialfibrillation after ablation / Mainigi S., Sauer W., Cooper J., et al. // J CardiovascElectrophysiol. 2007 Jan; 18(1):69–74.104.Manganiello S. Symptomatic and asymptomatic long-term recurrencesfollowing transcatheter atrial fibrillation ablation / Manganiello S., AnselminoM., Amellone C., et al. // Pacing Clin Electrophysiol.
2014 Jun; 37(6):697–702.105.Massie B. Irbesartan in patients with heart failure and preserved ejectionfraction / Massie B., Carson P., McMurray J., et al. // N Engl J Med, 2008; 359:2456–67.106.Masuda M. The impact of atrial fibrillation ablation on left atrial function:association with baseline left atrial function / Masuda M., Inoue K., Iwakura K.,et al. // Pacing Clin Electrophysiol. 2012 Mar;35(3):327–34.107.Matsui Y. Role of matricellular proteins in cardiac tissue remodelling aftermyocardial infarction / Matsui Y., Morimoto J., Uede T.
// World J Biol Chem2010;1:69–80.108. McCready J. Predictors of recurrence following radiofrequency ablation forpersistent atrial fibrillation / McCready J., Smedley T., Lambiase P., et al. //Europace. 2011 Mar; 13 (3):355–61109.McMurray J. Effects of candesartan in patients with chronic heart failureand reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial / McMurray J., Ostergren J.,Swedberg K., et al. // Lancet, 2003; 362:767–71.110.Melek M.
The effect of successful electrical cardioversion on leftventricular diastolic function in patients with persistent atrial fibrillation: a tissueDoppler study / Melek M., Birdane A., Goktekin O., et al. // Echocardiogr MtKisco N. 2007;24 (1):34–9.111.Moe G. A computer model of atrial fibrillation / Moe G., Rheinboldt W.,Abildskov J., et al. // Am Heart J 1964; 67:200–20120112.Mont L.
Catheter ablation vs. antiarrhythmic drug treatment of persistentatrial fibrillation: a multicentre, randomized, controlled trial (SARA study) /Mont L., Bisbal F., Hernandez-Madrid A., et al. // Eur Heart J 2014; 35: 501–507.113.Nabauer M. The registry of the German competence NETwork on atrialfibrillation: patient characteristics and initial management / Nabauer M., GerthA., Limbourg T., et al. // Europace 2009; 11: 423–434.114.Nagueh S. Recommendations for the Evaluation of Left VentricularDiastolic Function by Echocardiography: An Update from the American Societyof Echocardiography and the European Association of Cardiovascular Imaging /Nagueh S., Smiseth O., Appleton C., et al.
// J Am Soc Echocardiogr. 2016 Apr;29(4):277–314.115.Nattel S. Arrhythmogenic ion-channel remodeling in the heart: heartfailure, myocardial infarction, and atrial fibrillation / Nattel S., Maguy A., LeBouter S., et al. // Physiol Rev. 2007; 87:425–456.116.Nattel S. Mechanisms of atrial fibrillation: lessons from animal models /Nattel S., Shiroshita-Takeshita A., Brundel B., et al.
// Prog Cardiovasc Dis.2005; 48:9–28.117.Nattel S. Basic mechanisms of atrial fibrillation–very new insights intovery old ideas /Nattel S., Li D., Yue L. // Annu Rev Physiol. 2000; 62:51–77.118.Nedios S. Long-termfollow-up after atrial fibrillation ablation in patientswith impaired left ventricular systolic func- tion: the importance of rhythm andrate control / Nedios S., Sommer P., Dagres N., et al.
// Heart Rhythm 2014;11:344–51.119.Oral H. Clinical significance of early recurrences of atrial fibrillation afterpulmonary vein isolation / Oral H., Knight B., Ozaydin M., et al. // J Am CollCardiol 2002; 40:100–104.120.Oral H. Prevalence of asymptomatic recurrences of atrial fibrillation aftersuccessful radiofrequency catheter ablation /Oral H., Veerareddy S., Good E., etal. // J Cardiovasc Electrophysiol.
2004 Aug; 15(8):920–4.121121.Packer D. Cryoballoon ablation of pulmonary veins for paroxysmal atrialfibrillation: first results of the North American Arctic Front (STOP AF) pivotaltrial / Packer D., Kowal R., Wheelan K., et al. // J Am Coll Cardiol. 2013;61:1713–1723.122.Park Y. Intra-procedural imaging of the left atrium and pulmonary veinswith rotational angiography: a comparison of anatomy obtained by preprocedural cardiac computed tomography and trans-thoracic echocardiography /Park Y., Kim M., Choi J., et al.
// Int J Cardiovasc Imaging. 2013 Oct;29(7):1423-32.123.Parkash R. Effect of Aggressive Blood Pressure Control on the Recurrenceof Atrial Fibrillation After Catheter Ablation: A Randomized, Open-LabelClinical Trial (SMAC-AF [Substrate Modification With Aggressive BloodPressure Control]) / Parkash R., Wells G., Sapp J., et al. // 2017 May9;135(19):1788–1798.124.Patil V. Diastolic dysfunction in asymptomatic type 2 diabetes mellituswith normal systolic function / Patil V., Patil H., Shah K., et al. // J CardiovascDis Res.
2011; 2:213–222.125.Pathak R. Aggressive risk factor reduction study for atrial fibrillation andimplications for the outcome of ablation: the ARREST-AF cohort study / PathakR., Middeldorp M., Lau D., et al. // J Am Coll Cardiol. 2014 Dec 2;64(21):2222–31.126.Phan T. The pathophysiology of heart failure with preserved ejectionfraction: from molecular mechanisms to exercise haemodynamics / Phan T.,Shivu G., Abozguia K., et al. // Int J Cardiol 2012; 158:337–343127.Piorkowski C. Value of different follow-up strategies to assess the efficacyof circumferential pulmonary vein ablation for the curative treatment of atrialfibrillation / Piorkowski C., Kottkamp H., Tanner H., et al. // J CardiovascElectrophysiol.
2005 Dec; 16(12):1286–92.128.Pokushalov E. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring / Pokushalov E.,122Romanov A., Corbucci G., et al. // J Cardiovasc Electrophysiol. 2011 Apr;22(4):369–75.129.Reant P. Reverse remodeling of the left cardiac chambers after catheterablation after 1 year in a series of patients with isolated atrial fibrillation /ReantP., Lafitte S., Ja ̈ıs P., et al. // Circulation 2005; 112:2896–2903.130.Rodrigues A.
Left atrial function after ablation for paroxysmal atrialfibrillation / Rodrigues A., Scannavacca M., Caldas M., et al. // The Americanjournal of cardiology. 2009;103(3):395–8.131.Rosenberg M. Diastolic dysfunction and risk of atrial fibrillation: amechanistic appraisal / Rosenberg M., Manning W.
// Circulation, 2012 Nov 6;126(19):2353–62.132.Rosenberg M. Echocardiographic diastolic parameters and risk of atrialfibrillation: the Cardio-vascular Health Study / Rosenberg M., Gottdiener J.,Heckbert S., et al. // Eur Heart J. 2012; 33:904–912.133.Ross J. Transseptal left atrial puncture: a new method for the measurementof left atrial pressure in man /Ross J., Braunwald E., Morrow A. // Am J Cardiol1959; 3:653–5.134.Santos S. Impact of Atrial Fibrillation Ablation on Left Ventricular FillingPressure and Left Atrial Remodeling /Santos S., Henz B., Zanatta A., et al.
// ArqBras Cardiol. 2014 Dec; 103(6):485–492135.Sawhney N. Circumferential pulmonary vein ablation with additional linearablation results in an increased incidence of left atrial flutter compared withsegmental pulmonary vein isolation as an initial approach to ablation ofparoxysmal atrial fibrillation / Sawhney N., Anousheh R., Chen W., et al.
// CircArrhythm Electrophysiol. 2010 Jun; 3(3):243–8.136.Schotten U. The role of atrial dilatation in the domestication of atrialfibrillation / Schotten U., Neuberger H., Allessie M., et al. // Prog Biophys MolBiol. 2003; 82: 151–162.137.Seldinger S. Catheter replacement of the needle in percutaneousarteriography; a new technique // Acta radiol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
